US10376540B2 - Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques - Google Patents

Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques Download PDF

Info

Publication number
US10376540B2
US10376540B2 US15/327,292 US201415327292A US10376540B2 US 10376540 B2 US10376540 B2 US 10376540B2 US 201415327292 A US201415327292 A US 201415327292A US 10376540 B2 US10376540 B2 US 10376540B2
Authority
US
United States
Prior art keywords
mammal
tungsten
fertility
composition
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/327,292
Other versions
US20170173074A1 (en
Inventor
Ignacio CANALS ALMAZÁN
Agnès ARBAT BUGIÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxolike SL
Oxolife SL
Original Assignee
Oxolike SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxolike SL filed Critical Oxolike SL
Assigned to OXOLIFE, S.L. reassignment OXOLIFE, S.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CANALS ALMAZÁN, Ignacio, ARBAT BUGIÉ, Agnès
Publication of US20170173074A1 publication Critical patent/US20170173074A1/en
Application granted granted Critical
Publication of US10376540B2 publication Critical patent/US10376540B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G41/00—Compounds of tungsten
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G41/00—Compounds of tungsten
    • C01G41/02—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Fertility in mammals is a multistage process that is not totally efficient naturally. Factors such as age, eating habits or life style, among others, modulate the success of this process. In this sense, it is known for example that pregnancy rate in women 20 to 24 years of age is about 86%, while it diminishes to 50% in women 35 to 32 years of age [ Management of the Infertile Women by Helen A. Carcio; The Fertility Sourcebook by M. Sara Rosenthal, ASAS Summary of FAIR 2012]. Other factors such as overweight or underweight are also responsible for delays in achieving pregnancy naturally or even for the impossibility in achieving same [ Fertil Steril 2013; 100:631-7].
  • the percentage of pregnancies achieved by means of the aforementioned treatments has limitations. In this sense, for example, it has been observed that treatment of women with irregular or no ovulation by means of administering clomiphene citrate, a drug of the stilbene family, allows restoring ovulation in a high percentage, but the pregnancy rate remains low, equal to or less than about 50%.
  • metabolic disorders such as diabetes or obesity entail a limitation of fertility. It is known that partial or complete recovery of glycemia, insulinemia and/or body weight in diabetic or obese female mice with damaged reproductive function, involves an improvement in fertility.
  • Tungsten is found in trace amounts in animals and plants. For example, tungsten content of up to a maximum of 100 mg/kg has been described in plants [Gbaruko B. C. & Igwe J. C. Global Tungsten: Occurrence, Chemistry, Environmental and Health Exposure Issues. Journal of Environmental Research 2007; 1(1):27-32].
  • tungsten (VI) salt or a solvate of said salt is effective for treating infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal, and for increasing the efficacy of assisted reproductive techniques applied to a mammal.
  • assisted reproductive technique encompasses any assisted reproductive technique or artificial insemination, being understood as a group of biomedical techniques or methods facilitating or replacing at least one of the natural processes taking place during reproduction. They include, but are not limited to, induction of ovulation, artificial insemination (including insemination with donor's sperm) and in vitro insemination (including insemination of a donor's ovum or insemination with donor's sperm).
  • said salt is administered in a daily dose between 0.001 mg and 1000 mg of tungsten (VI) salt per kg of body weight of the female mammal.
  • the tungsten (VI) salt comprises a tungsten (VI) anion and a pharmaceutically or veterinary acceptable cation.
  • “Pharmaceutically or veterinary acceptable cation” refers to any acceptable, non-toxic, organic or inorganic cation which is capable of forming a therapeutically effective tungsten (VI) salt and is suitable for use thereof in drug or veterinary therapy.
  • the cation is preferably an alkaline or alkaline earth cation.
  • the cation is more preferably selected from the group consisting of sodium, potassium, magnesium, calcium and zinc. According to a particular embodiment, the cation is sodium. According to another particular embodiment, the cation is zinc.
  • the solvate of the tungsten (VI) salt is a hydrate, more preferably a dihydrate.
  • the solvate of the tungsten (VI) salt is a dihydrate and the cation is a sodium cation.
  • the rest of the possible combinations is also intended to be included within the scope of the present invention.
  • excipients or vehicles suitable for use thereof in pharmaceutical, veterinary or food technologies for preparing the compositions. These components, excipients or carriers must be compatible with other ingredients of the composition. It must also be suitable for use thereof in contact with the tissue or organ of human beings and animals without excessive toxicity, irritation, allergic response or other immunogenicity problems or complications at a reasonable benefit/risk ratio. They are substances lacking pharmacological activity at the concentrations present in a pharmaceutical form.
  • the excipients or vehicles are used to provide the pharmaceutical or veterinary form characteristics which assure the stability, bioavailability, acceptability and ease of administration of one or more active ingredients.
  • excipients affect active ingredient release, they will be able to modify the magnitude and the time profile of the pharmacological activity of the drug product, by means of changes in its bioavailability.
  • the excipients are also used to provide the preparation with suitable form or consistency. Examples of types of excipients: solubilizers, disintegrants or disintegrating agents, emulsifiers (emulsifying agents), dyes, flavorings, binders, antioxidants, lubricants, preservatives, thickeners, etc.
  • the excipient or vehicle is pharmaceutically or veterinary acceptable
  • the composition is a pharmaceutical composition for the treatment of infertility in a non-diabetic female mammal or for increasing the efficacy of an assisted reproductive treatment applied to a mammal.
  • the pharmaceutical composition is preferably in the form of a pill, tablet, pastille, capsule, powder, wafer, effervescent powder or tablets, solution, suspension, syrup or granules.
  • the composition is a food composition for favoring normal reproduction and fertility in a non-diabetic female mammal.
  • the food composition can be a liquid composition or beverage, a solid composition or a nutritional supplement or complement (also referred to as dietary or food supplement or complement).
  • a nutritional supplement or complement also referred to as dietary or food supplement or complement.
  • the term “food composition” would encompass any solid or liquid food enriched with tungsten (VI) salt as well as any nutritional supplement or complement containing at least one tungsten (VI) salt.
  • the food composition can be a liquid composition, i.e., a beverage, according to terms most generally used in the society.
  • liquid composition includes, but is not limited to, any beverage selected from the group consisting of animal or plant milk, as well as any derivative thereof, such as for example, milk shakes, yogurt, kefir, etc.; fruit and/or vegetable juices; still water or sparkling water, or flavored or sweetened (by means of nutritive sweeteners (sucrose, fructose . . .
  • the food composition can also be a solid composition.
  • Such solid composition can, for example, be selected from, but is not limited to, the group consisting of animal or plant milk derivatives, such as cheese, butter, margarine and tofu; any type of bread, including fresh, packaged or frozen bread, sliced bread, wholemeal bread, spiced bread, sweet bread, salty bread, etc; pasta prepared from any cereal flour, such as wheat or semolina flour (macaroni, spaghetti, noodles, etc); baked goods, including cakes, cookies, muffins, doughnuts, etc.; infusions, tea or coffee, in bulk or in sachets, for preparing beverages; jellies, candies, including gummy candies, better known as “soft fruit candies”; as well as any type of solid seasoning, for example, oregano, salt, coriander, parsley, basil, etc, or mixtures thereof.
  • animal or plant milk derivatives such as cheese, butter, margarine and tofu
  • any type of bread including fresh, packaged or frozen bread
  • the food composition can also be a nutritional, dietary or food supplement or complement, any of these terms being used in the context of the present invention in an equivalent manner.
  • These terms are normally used for compositions consumed orally, which contain an ingredient intended for complementing the diet, in the case of the present invention, the tungsten (VI) salt/salts. They shall never replace a conventional food, or be the only component of a meal or of the diet. They can be found in different presentations, such as pastilles, pills, tablets, capsules, soft gelatin capsules, gelatin capsules, wafers, effervescent tablets, liquids (solution, suspension, syrup), granules and powders, all of which are included as particular embodiments within the scope of the present invention. Dietetically or pharmaceutically acceptable excipients are obvious for the skilled person for obtaining any of the preceding presentations, and they are included within the scope of the present invention.
  • any of the preceding compositions comprises in their composition at least one nutritive sweetener, such as sucrose or fructose. Ingestion of these nutritive sweeteners must be controlled and limited in diabetic patients, therefore a food composition including such nutritive sweetener would be contraindicated in diabetic mammals or would at least be taken into account in controlling their diet.
  • at least one nutritive sweetener such as sucrose or fructose. Ingestion of these nutritive sweeteners must be controlled and limited in diabetic patients, therefore a food composition including such nutritive sweetener would be contraindicated in diabetic mammals or would at least be taken into account in controlling their diet.
  • the non-diabetic female mammal is selected from the group consisting of female mammals that require restoring and/or promoting ovulation, improving oocyte and embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary-ovarian axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia.
  • female mammals that require restoring and/or promoting ovulation, improving oocyte and embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary-ovarian axis impairment, including polycy
  • the non-diabetic female mammal is selected from the group consisting of female mammals having insulin resistance (also known as resistance to insulin or insulinic resistance); when insulin resistance occurs together with hyperglycemia, it can lead to the development of diabetes, nevertheless insulin resistance alone does not lead to a diabetic condition.
  • insulin resistance also known as resistance to insulin or insulinic resistance
  • the female mammals having insulin resistance are preferably selected from the group consisting of female mammals having one or more of the following conditions: obesity or overweight, metabolic syndrome, prediabetes, polycystic ovarian syndrome, hypertension, heart disease, hyperlipidemias or dyslipidemia, hyperthyroidism, hyperparathyroidism, hyperleptinemia or leptin resistance, sedentary life style, eating disorders, obstructive sleep apnea syndrome, fetal malnutrition, Prader-Willi syndrome, Rabson-Mendenhall syndrome, fatty liver, leprechaunism, pathologies associated with excessive glucocorticoid secretion (e.g., acromegaly), insulin resistance caused by pharmacological treatments (e.g., glucocorticoids, thiazide diuretics, beta-blockers), stress or early menarche [Egas Béjar, Daniela et.
  • pharmacological treatments e.g., glucocorticoids, thia
  • the salt or tungsten (VI) salts or a solvate thereof are present at a concentration of at least 100 mg/kg.
  • the salt or tungsten (VI) salts are comprised in the composition at concentrations of at least 150 mg/kg, at least 200 mg/kg, at least 250 mg/kg, at least 300 mg/kg, at least 350 mg/kg, at least 400 mg/kg, at least 450 mg/kg, at least 500 mg/kg, at least 550 mg/kg, at least 600 mg/kg, at least 650 mg/kg, at least 700 mg/kg, at least 750 mg/kg, at least 800 mg/kg, at least 850 mg/kg, at least 900 mg/kg or at least 850 mg/kg.
  • a third aspect of the invention relates to the use of a tungsten (VI) salt or a solvate thereof, as defined above, for the preparation of a medicinal product for the treatment of infertility in a non-diabetic female mammal or for favoring fertility in a non-diabetic female mammal.
  • a fourth aspect of the invention relates to a method for the treatment of infertility or for favoring normal reproduction and fertility in a non-diabetic female mammal, which comprises administering a therapeutically effective amount of a tungsten (VI) salt or a solvate thereof, as defined above.
  • a tungsten (VI) salt or a solvate thereof as defined above.
  • the mouse model used for determining the activity of tungsten (VI) salts for favoring normal reproduction and fertility is an Irs2 gene knock-out mouse, IRS2 ⁇ / ⁇ [Burks et. al., “ IRS -2 pathways integrate female reproduction and energy homeostasis”, Nature, 2000, vol. 407, pp. 377-382]. Irs2 gene deletion translates into a clear sexual dimorphism in relation to fertility and carbohydrate metabolism.
  • the male mice of this model have insulin resistance and severe hyperglycemia that started at an early age.
  • the female mice remain relatively euglycemic at an early age and develop slight insulin resistance which remains until a later age (4-5 months).
  • IRS2 ⁇ / ⁇ female mice at an early age about 10 weeks old, show a low follicular development and persistent anovulation, accompanied by the absence of estrous cycle in most mice.
  • the pregnancy rate in IRS2 ⁇ / ⁇ female mice is 9% compared to the rate of 100% in IRS wt (IRS-2 ⁇ / ⁇ wild type) female mice. Given that female mice at these ages remain euglycemic and that they only develop slight insulin resistance, the profound impairment in fertility is not a direct result of anomalies in glucose metabolism.
  • the IRS2 ⁇ / ⁇ female mice used are between 6 and 8 weeks of age.
  • IRS2 has critical and direct functions on the ovary, particularly in follicular development and ovulation, by means of regulating key components of the cell cycle mechanism that are involved in cell proliferation and differentiation coordination, clearly and directly linking the absence of IRS2 expression with infertility [Biology of Reproduction 2007, 76, 1045-1053].
  • the IRS2 ⁇ / ⁇ animal model is primarily a beta-cell failure model [Am J Physiol Endocrinol Metab 2014, 306, E36-E47)]. It describes that the progressive loss of beta cells due to the increased number of apoptotic beta cells determine the progression to diabetes in this animal model (see page E36, column 2, paragraph 2), only at advanced ages. The gradual reduction of beta cells is initially compensated for by a higher activity of persisting cells, and only in advanced ages, the decrease in the number of cells cannot be compensated for by the persisting cells, giving rise to the onset of hyperglycemia and the subsequent development of diabetes
  • this animal model covers a series of important infertility-related factors and is a suitable model for studying the efficacy of the compounds on infertility in female mammals.
  • IRS2 ⁇ / ⁇ female mice of ages comprised between 6 and 8 weeks.
  • Six “wild-type” (IRS2 wt ) male mice of ages comprised between 6 and 8 weeks.
  • the female and male mice were housed separately in normal conditions, i.e., a 12 h light/darkness cycle and controlled temperature and humidity.
  • the animals were fed at will (also referred to as ad libitum) with a standard feed diet.
  • the IRS2 ⁇ / ⁇ female mice were housed in groups of 4-6 mice/cage. Tungstate salt-free drinking water was administered to the animals during the pre-treatment phase (2 weeks).
  • the IRS2 ⁇ / ⁇ female mice were housed in cages in pairs together with a IRS2 wt male mouse continuously.
  • mice were observed daily to look for signs of pregnancy or birth.
  • mice After 4 weeks, the male mice were exchanged between the cages and they were kept therein for another 4 weeks.
  • the administration of tungstate was maintained for 8 weeks in which male and female mice were housed together. After these 8 weeks, treatment was withdrawn and the male and female mice were housed together for 4 additional weeks.
  • vaginal smears were performed in 6 randomly chosen female mice on days ⁇ 8; ⁇ 5; ⁇ 2; ⁇ 1; 7; 8; 14; 15 and 22, to determine the phase of the estrous cycle they were in.
  • the Papanicolau technique comprises staining the vaginal smears fixed on the slide in the following manner:
  • the preparations were analyzed by trained staff using a coding in a single-blind manner for eliminating observer bias.
  • the samples were identified in the following phases: diestrus, proestrus, estrus, metestrus, anestrus or non-evaluable.
  • the cyclical nature of the four phases in periods of 4 to 6 days are indicative of a normal estrous cycle, whereas the absence of this cyclical nature and the persistence in anestrus, diestrus or proestrus phases are indicative of the absence of estrous cycle.
  • Table 1 summarizes the phases of the estrous cycle in the vaginal smears performed in 6 of these IRS2 ⁇ / ⁇ female mice.
  • the phases of the estrous cycle are the following: A: Anestrus; D: Diestrus; P: Proestrus; E: Estrus; and M: Metestrus.
  • the phases of the estrous cycle found in the vaginal smears of the IRS2 ⁇ / ⁇ female mice of Table 1 show that during the pre-treatment period all the mice were in the proestrus (P) or diestrus (D) phase, i.e., with the absence of estrous cycle.
  • tungsten (VI) salt is an effective treatment for recovering ovulation and/or increasing oocyte implantation. Therefore, the administration of a tungsten (VI) salt as defined in the present invention is effective for the treatment of infertility in non-diabetic female mammals.
  • mice The female mice were housed in normal conditions, i.e., a 12 h light/darkness cycle and controlled temperature and humidity. The animals were fed at will (also referred to as ad libitum) with a standard feed diet.
  • sodium tungstate was administered in the drinking water (ad libitum) by means of a solution of 2 mg/ml of sodium tungstate dihydrate (marketed by Carlo Erba) in distilled water after the pre-treatment phase (day 0 of treatment) and for 12 days.
  • the body weight was monitored on days 0, 2, 5, 7, 9 and 12 of the treatment period, and the blood glucose was determined after 6 hours of fasting on each of the aforementioned days by means of drawing blood from the tail vein and with a glucose sensor (AccuTrend glucose sensor, Roche, Mannheim, Germany).
  • a glucose sensor Acceletrend glucose sensor, Roche, Mannheim, Germany.
  • Table 3 summarizes the glycemic levels expressed in mg/dl
  • Table 4 summarizes the body weight of the mice under study expressed in grams.
  • Glycemia (mg/dl) Aver- R1327 R1345 R1347 R1354 R1376 R1381 age Day 0 146 129 115 126 141 112 128,17 Day 2 136 128 118 110 105 107 117,33 Day 5 125 142 114 111 137 105 122,33 Day 7 140 110 106 89 133 135 118,83 Day 9 125 153 109 108 131 125 125,17 Day 12 136 116 111 86 123 141 118,83
  • tungsten (VI) salt is a treatment effective for recovering ovulation and/or increasing oocyte implantation, regardless of the changes in body weight and in carbohydrate metabolism. It is therefore demonstrated that the administration of a tungsten (VI) salt as defined in the present invention or a composition containing such tungsten (VI) salt has a direct effect on the female reproductive system and is therefore effective for favoring normal reproduction and fertility in non-diabetic female mammals.
  • in vitro models and specifically the model based on the mentioned cell lines (HEC-1A and JEG-3), is considered a standard model for studying endometrial receptivity and particularly the adhesion the trophoblast to the endometrium (Fertility and Sterility 2011; 96, 522-529; Methods in Enzymology 2006; 420:3-18 or FASEB J. 201; 26:3715-3727).
  • the JEG-3 cell line which simulates the trophectoderm cells of a human embryo are cells that grow in monolayers in laboratory using low adherence plates and are capable of forming spheroids simulating the human embryo; this is one of the most widely used cell lines for conducting in vitro embryonic adhesion assay.
  • the cell lines were commercially purchased (American Type Culture Collection (ATCC); Rockville, Md., USA) for conducting the endometrial embryonic adhesion experiments. They were thawed and expanded in 4 passes for obtaining sufficient cells to perform all the assays.
  • the JEG-3 cells were plated in low adherent plates with Eagle's minimal essential medium (EMEM) culture medium supplemented with 10% fetal bovine serum and 0.1% antibiotics (fungizone and penicillin). Twenty-four hours before the adhesion assay, the JEG-3 trophoblast spheroids were formed from this culture. To that end, JEG-3 cells in the medium described above were suspended in an Erlenmeyer flask under stirring at a concentration of 6 ⁇ 10 5 cells/6 ml. The resulting spheroids were collected for the adhesion assay.
  • EMEM Eagle's minimal essential medium
  • antibiotics fungizone and penicillin
  • the adhesion assay 24 hours after culturing the HEC-1A cells with culture medium adding sodium tungstate, Withaferin A or without adding any treatment, the culture medium was changed with fresh culture medium without treatments under study.
  • the trophectoderm spheroids were added onto the monolayer of HEC-1A cells, placing 6 to 10 spheroids per well.
  • the adhesion of the spheroids was measured after 60 minutes, counting spheroid that was floating in the culture medium as non-adhered spheroid and spheroid that was not floating as adhered spheroid.
  • the examination was conducted with an inverted microscope (Nikon Diaphot 300; Nikon Corp., Tokyo, Japan).
  • the assay was conducted in triplicate.
  • a tungsten salt-enriched salad dressing is prepared. An amount of 25 mg of Na 2 WO 4 (100 mg/kg) is added to 250 grams of a commercially available dressing and it is mechanically stirred for 30 minutes.
  • a tungsten salt-enriched ketchup-type salsa is prepared. To that end, 170 mg of CaWO 4 are added to 200 grams of commercially available ketchup and it is mechanically stirred for 1 hour.
  • a tungsten salt-enriched milk is prepared. To that end, 1 kg of whole cow's milk is provided, 150 mg of ZnWO 4 are added and it is mechanically stirred for 20 minutes. It is recommended to shake the packaging immediately before consumption.
  • a tungsten salt-enriched fruit juice is prepared. Five-hundred mg of MgWO 4 are added to 1 kg of commercial juice and it is mechanically stirred for 10 minutes. It is recommended to shake the packaging immediately before consumption.
  • Effervescent tablets with the following composition are prepared:
  • Gelatin capsules with the following composition are prepared:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Powder Metallurgy (AREA)
  • Radiation-Therapy Devices (AREA)
  • Electroplating And Plating Baths Therefor (AREA)
  • Inorganic Insulating Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)

Abstract

The invention relates to tungsten (VI) salts for use thereof in the treatment of infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal, or for increasing the efficacy of an assisted reproductive technique applied to a mammal, as well as compositions containing same and methods for treatment using same.

Description

RELATED APPLICATIONS
This application is a 35 U.S.C. § 371 national stage filing of International Application No. PCT/ES2014/070586, filed on Jul. 21, 2014, the entire contents of which are incorporated herein by reference.
The present invention relates to tungsten (VI) salts and compositions containing same, for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of an assisted reproductive technique applied to a mammal.
PRIOR ART
Fertility in mammals is a multistage process that is not totally efficient naturally. Factors such as age, eating habits or life style, among others, modulate the success of this process. In this sense, it is known for example that pregnancy rate in women 20 to 24 years of age is about 86%, while it diminishes to 50% in women 35 to 32 years of age [Management of the Infertile Woman by Helen A. Carcio; The Fertility Sourcebook by M. Sara Rosenthal, ASAS Summary of FAIR 2012]. Other factors such as overweight or underweight are also responsible for delays in achieving pregnancy naturally or even for the impossibility in achieving same [Fertil Steril 2013; 100:631-7]. It is estimated that about 66% of couples do not conceive naturally during the first 3 months of unprotected sexual intercourse. This figure decreases to 15% of couples in the course of the first year of unprotected sexual intercourse. Infertility is defined (WHO, ASRM, NICE) as the inability to conceive after 12 months of regular, unprotected sexual intercourse. The term “subfertility” has also been coined, particularly in Europe, to define those couples with any form or degree of reduced fertility leading to delay in conception [Gnoth C et al Definition and prevalence of subfertility and infertility, Human reproduction 2005; 20(5):1144-1147].
The main causes of infertility among women include ovulatory dysfunctions, pathologies of the reproductive tract, reduced oocyte quality and follicular depletion inherent to aging. However, there is also a considerable percentage of women with unexplained infertility, also referred to as idiopathic infertility, one of the possible causes of which relates to deficiencies in the implantation process.
Follicular development, ovulation, migration of immature egg (oocyte), as well as subsequent conception and zygote implantation on the uterine wall is regulated by hormonal secretions of certain endocrine organs such as the pituitary gland, the hypothalamus and the thyroid gland, for example. Among the different biological causes of infertility in women, causes linked to disorders in the hormonal stimuli regulating this whole process can also be pointed out.
Different treatments for female infertility including, among others, the administration of medicinal products for treating hormonal problems involving ovulation disruption (such as, clomiphene citrate or gonadotropins, for example), are known. Likewise, some beneficial effects have been postulated with various treatments based on taking vitamin supplements, particularly vitamin B, vitamin C, vitamin E and folic acid, mineral supplements such as selenium, zinc or iron complexes or salts, essential fatty acids (omega-3), as well as extracts from plants such as chaste tree (Vitex agnus-castus), damiana, licorice, red clover flower, chasteberry, black cohosh, dong quai (Angelica sinensis), wild yam or sweet potato (Dioscorea villosa), false unicorn root, green tea, nettles (Urtica dioica), wild oats (Avena sativa), dandelion (Taraxacum officinale), etc., although the efficacy has not been clearly demonstrated in any of these treatments.
The percentage of pregnancies achieved by means of the aforementioned treatments has limitations. In this sense, for example, it has been observed that treatment of women with irregular or no ovulation by means of administering clomiphene citrate, a drug of the stilbene family, allows restoring ovulation in a high percentage, but the pregnancy rate remains low, equal to or less than about 50%.
In vitro fertilization treatments are very effective in the oocyte fertilization step. However, the embryo implantation rate on the uterine wall is low. This promotes multiple embryo transfers per each in vitro fertilization cycle, with the consequence of a higher percentage of risky multiple pregnancies.
Finally, it is known that metabolic disorders such as diabetes or obesity entail a limitation of fertility. It is known that partial or complete recovery of glycemia, insulinemia and/or body weight in diabetic or obese female mice with damaged reproductive function, involves an improvement in fertility.
Different pharmacological treatments, such as metformin or tungsten (VI) salts, or even life style changes, have been shown to improve diabetes or insulin disorders, such as insulin deficiency or insulin resistance, for example, completely or partially recovering the reproductive function, when the infertility is due to diabetes or insulin disorders.
In the specific case of sodium tungstate, it is known that rats with diabetes and insulinopenia induced by the injection of streptozotocin partially recover circulating insulin levels after a prolonged treatment (10 weeks) with sodium tungstate as a result of partially reversing diabetes. Subsequently, when the female rats partially recovered from diabetes mate with healthy male rats, it is observed that, parallel to the partial recovery from diabetes, they have partially recovered their reproductive capacity. Particularly, it is observed that the percentage of births with respect to the number of positive curettages in female mice which had partially recovered from diabetes after treatment with sodium tungstate increases to 66%, a percentage which is lower than non-diabetic female mice where the percentage is 100%. (cf. J. Ballester et. al., “Tungstate administration improves the sexual and reproductive function in female rats with streptozotocin-induced diabetes”, Human Reproduction, 2007, vol. 22, pp. 2128-2135). Nevertheless, the tungsten (VI) salts were neither observed nor postulated to have effect on non-diabetic female animals.
Tungsten is found in trace amounts in animals and plants. For example, tungsten content of up to a maximum of 100 mg/kg has been described in plants [Gbaruko B. C. & Igwe J. C. Global Tungsten: Occurrence, Chemistry, Environmental and Health Exposure Issues. Journal of Environmental Research 2007; 1(1):27-32].
In view of the foregoing, despite the extensive research and progress in understanding and handling the reproductive process in mammals and particularly in humans, there are still many couples who do not benefit from the different approaches available today for increasing fertility as they are ineffective. Therefore, there is still a need to find new alternatives for improving natural reproductive efficiency and/or treating female infertility that provide greater efficacy.
DISCLOSURE OF THE INVENTION
It has now been found that the administration of a tungsten (VI) salt or a solvate of said salt is effective for treating infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal, and for increasing the efficacy of assisted reproductive techniques applied to a mammal. Despite the fact that sodium tungstate was known to be able to partially reverse impairments in the reproductive function of diabetic female mice because it normalizes blood glucose levels, the possibility of sodium tungstate having an effect on the function of the female reproductive system in non-diabetic female mammals, being presented as a treatment for infertility and/or favoring normal reproduction and fertility in non-diabetic female mammals, has not been described nor suggested. The efficacy of the administration of a tungsten salt for treating infertility or for improving or normalizing fertility has now been demonstrated through an animal model, specifically IRS2−/− female mice, as reflected in the examples of the present invention. An effect of tungsten salts on embryo implantation has also been demonstrated in the same animal model indicated above, as well as a positive effect on endometrial embryonic adhesion, based on an in vitro assay, the results of which also indicated in the examples.
Therefore, a first aspect of the present invention relates to a tungsten (VI) salt or a solvate thereof, for use thereof for the treatment of infertility in a non-diabetic female mammal or for favoring normal reproduction and fertility in a non-diabetic female mammal.
A second aspect of the present invention relates to a composition comprising a tungsten (VI) salt or a solvate thereof at a concentration greater than 100 mg/kg, as well as at least one pharmaceutically or dietetically acceptable excipient or vehicle, for the treatment of infertility in a non-diabetic female mammal or for favoring normal reproduction and fertility in a non-diabetic female mammal.
A third aspect of the invention relates to the use of a tungsten (VI) salt or a solvate thereof, as defined above, for the preparation of a medicinal product for the treatment of infertility in a non-diabetic female mammal or for favoring fertility in a non-diabetic female mammal.
A fourth aspect of the invention relates to a method for the treatment of infertility or for favoring normal reproduction and fertility in a non-diabetic female mammal, which comprises administering a therapeutically effective amount of a tungsten (VI) salt or a solvate thereof, as defined above.
DETAILED DISCLOSURE OF THE INVENTION
As indicated above, according to a first aspect the present invention relates to a tungsten (VI) salt or a solvate thereof, for the treatment of infertility in a non-diabetic female mammal or for favoring and/or contributing to normal reproduction and fertility in a non-diabetic female mammal.
The term “favoring normal reproduction and fertility” or “contributing to normal reproduction and fertility” refers to contributing to normal reproduction and fertility or improving normal reproduction and fertility (reducing the times for achieving pregnancy), “normal reproduction and fertility” being understood as a state of fertility in which pregnancy is achieved following the definitions provided above:
    • in a subfertility situation: pregnancy is achieved in a period of 12 months of regular, unprotected sexual intercourse; and
    • in an infertility situation: pregnancy is achieved after a period 12 months of regular, unprotected sexual intercourse. The need to restore and/or promote ovulation, improve oocyte and embryo quality, increase zygote implantation on the uterine wall, regulate hypothalamic-pituitary-ovarian axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia are included herein.
In the context of the present invention, the term “assisted reproductive technique” encompasses any assisted reproductive technique or artificial insemination, being understood as a group of biomedical techniques or methods facilitating or replacing at least one of the natural processes taking place during reproduction. They include, but are not limited to, induction of ovulation, artificial insemination (including insemination with donor's sperm) and in vitro insemination (including insemination of a donor's ovum or insemination with donor's sperm). Therefore, the assisted reproductive technique can be applied due to causes of infertility or reduced fertility, both in a female mammal (as defined above) and in a male mammal (for example, alterations of spermatozoids reflected in a seminogram, such as alterations of spermatozoid mobility, alterations of spermatozoid vitality, as well as alterations of spermatozoid morphology). The assisted reproductive technique can also be applied in women who, despite not having any fertility problem per se, must resort to the technique for various reasons, for example (but not limited to), women without a partner who require sperm donation, couples who have to resort to ovum and/or sperm donation due to genetic or another type of incompatibilities, or livestock that require embryo transfer for improved productivity. These assisted reproductive techniques generally have a reduced success rate of less than 50% or even 40%. That is due to the fact that the use of assisted reproductive techniques has an inherent reduction in the efficiency of reproductive process. One of the main causes of this low reproductive efficiency with the use of assisted reproductive techniques relates to difficulties in the embryo adhesion and implantation process.
In the context of the present invention, the term “improving” in the expression “improving the efficacy of an assisted reproductive technique” refers to increasing the success rate of such assisted reproductive techniques. Therefore, if the success rate in the age range of the mammalian couple on which the assisted reproductive technique is applied was, according to previous statistics, 43%, for example, a higher rate from 44% would involve an improvement in the efficacy of such technique. This improvement is mainly due to favoring embryo adhesion and implantation as a result of administering tungsten (VI) salts.
Even though the assisted reproductive technique is applied due to an alteration in the fertility of the male mammal of the couple, by improving embryo adhesion and implantation, the tungsten (VI) salts will be administered at least to the female mammal. Alternatively, the tungsten (VI) salts can be administered to both the female mammal and the male mammal.
The mammal in the context of the present invention can be any mammal, including, but not limited to, humans, mice, rats, rabbits, dogs, cats, guinea pigs, hamsters, cows, horses, pigs, sheep, goats, etc. According to a particular embodiment, the mammal is a human.
According to another particular embodiment, said salt is administered in a daily dose between 0.001 mg and 1000 mg of tungsten (VI) salt per kg of body weight of the female mammal.
In another particular embodiment, the tungsten (VI) salt comprises a tungsten (VI) anion and a pharmaceutically or veterinary acceptable cation. “Pharmaceutically or veterinary acceptable cation” refers to any acceptable, non-toxic, organic or inorganic cation which is capable of forming a therapeutically effective tungsten (VI) salt and is suitable for use thereof in drug or veterinary therapy. The cation is preferably an alkaline or alkaline earth cation. The cation is more preferably selected from the group consisting of sodium, potassium, magnesium, calcium and zinc. According to a particular embodiment, the cation is sodium. According to another particular embodiment, the cation is zinc.
The tungsten (VI) anion in the tungsten (VI) salt is preferably selected from WO4 2−, HWO4 −, W2O7 2− and HW2O7 − ions. The anion is preferably WO4 2−.
According to an additional particular embodiment, the solvate of the tungsten (VI) salt is a hydrate, more preferably a dihydrate.
All the features listed individually for different elements of the invention can be combined with one another, all the possible combinations being included within the scope of the present invention. For example, according to a preferred embodiment the solvate of the tungsten (VI) salt is a dihydrate and the cation is a sodium cation. Similarly, the rest of the possible combinations is also intended to be included within the scope of the present invention.
An additional aspect of the invention is a composition comprising a tungsten (VI) salt or a solvate thereof as defined above at a concentration equal to or greater than 100 mg/kg and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, for the treatment of infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal, or for increasing the efficacy of an assisted reproductive technique applied to a mammal.
The term “pharmaceutically, veterinary or dietetically acceptable excipient or vehicle” refers to excipients or vehicles suitable for use thereof in pharmaceutical, veterinary or food technologies for preparing the compositions. These components, excipients or carriers must be compatible with other ingredients of the composition. It must also be suitable for use thereof in contact with the tissue or organ of human beings and animals without excessive toxicity, irritation, allergic response or other immunogenicity problems or complications at a reasonable benefit/risk ratio. They are substances lacking pharmacological activity at the concentrations present in a pharmaceutical form. The excipients or vehicles are used to provide the pharmaceutical or veterinary form characteristics which assure the stability, bioavailability, acceptability and ease of administration of one or more active ingredients. As regards the extent to which the excipients affect active ingredient release, they will be able to modify the magnitude and the time profile of the pharmacological activity of the drug product, by means of changes in its bioavailability. The excipients are also used to provide the preparation with suitable form or consistency. Examples of types of excipients: solubilizers, disintegrants or disintegrating agents, emulsifiers (emulsifying agents), dyes, flavorings, binders, antioxidants, lubricants, preservatives, thickeners, etc.
According to a preferred embodiment, the excipient or vehicle is pharmaceutically or veterinary acceptable, and the composition is a pharmaceutical composition for the treatment of infertility in a non-diabetic female mammal or for increasing the efficacy of an assisted reproductive treatment applied to a mammal.
The pharmaceutical composition is preferably in the form of a pill, tablet, pastille, capsule, powder, wafer, effervescent powder or tablets, solution, suspension, syrup or granules.
According to another preferred embodiment, the composition is a food composition for favoring normal reproduction and fertility in a non-diabetic female mammal.
The food composition can be a liquid composition or beverage, a solid composition or a nutritional supplement or complement (also referred to as dietary or food supplement or complement). In the context of the present invention, the term “food composition” would encompass any solid or liquid food enriched with tungsten (VI) salt as well as any nutritional supplement or complement containing at least one tungsten (VI) salt.
The food composition can be a liquid composition, i.e., a beverage, according to terms most generally used in the society. In the context of the present invention, such liquid composition includes, but is not limited to, any beverage selected from the group consisting of animal or plant milk, as well as any derivative thereof, such as for example, milk shakes, yogurt, kefir, etc.; fruit and/or vegetable juices; still water or sparkling water, or flavored or sweetened (by means of nutritive sweeteners (sucrose, fructose . . . ) or artificial sweeteners) water or beverages; seasonings, such as for example, any salsa, dressing, ketchup, oil, vinegar or vinegar preparations; alcoholic beverages of any type; tea, coffee; as well as all types of refreshing beverages or soft drinks, or energizing beverages.
The food composition can also be a solid composition. Such solid composition can, for example, be selected from, but is not limited to, the group consisting of animal or plant milk derivatives, such as cheese, butter, margarine and tofu; any type of bread, including fresh, packaged or frozen bread, sliced bread, wholemeal bread, spiced bread, sweet bread, salty bread, etc; pasta prepared from any cereal flour, such as wheat or semolina flour (macaroni, spaghetti, noodles, etc); baked goods, including cakes, cookies, muffins, doughnuts, etc.; infusions, tea or coffee, in bulk or in sachets, for preparing beverages; jellies, candies, including gummy candies, better known as “soft fruit candies”; as well as any type of solid seasoning, for example, oregano, salt, coriander, parsley, basil, etc, or mixtures thereof.
Finally, the food composition can also be a nutritional, dietary or food supplement or complement, any of these terms being used in the context of the present invention in an equivalent manner. These terms are normally used for compositions consumed orally, which contain an ingredient intended for complementing the diet, in the case of the present invention, the tungsten (VI) salt/salts. They shall never replace a conventional food, or be the only component of a meal or of the diet. They can be found in different presentations, such as pastilles, pills, tablets, capsules, soft gelatin capsules, gelatin capsules, wafers, effervescent tablets, liquids (solution, suspension, syrup), granules and powders, all of which are included as particular embodiments within the scope of the present invention. Dietetically or pharmaceutically acceptable excipients are obvious for the skilled person for obtaining any of the preceding presentations, and they are included within the scope of the present invention.
According to a particular embodiment, any of the preceding compositions (pharmaceutical composition, solid composition, liquid composition or nutritional supplement/complement) comprises in their composition at least one nutritive sweetener, such as sucrose or fructose. Ingestion of these nutritive sweeteners must be controlled and limited in diabetic patients, therefore a food composition including such nutritive sweetener would be contraindicated in diabetic mammals or would at least be taken into account in controlling their diet.
According to a particular embodiment, the non-diabetic female mammal is selected from the group consisting of female mammals that require restoring and/or promoting ovulation, improving oocyte and embryo quality, increasing zygote implantation on the uterine wall, regulating hypothalamic-pituitary-ovarian axis impairment, including polycystic ovarian syndrome, metabolic syndrome, hyperprolactinemia, endometriosis, hypothyroidism, multiple sclerosis, rheumatoid arthritis, lupus erythematosus, cirrhosis, rheumatoid arthritis, celiac disease, chronic kidney failure, idiopathic causes and eating disorders, such as anorexia nervosa and bulimia.
According to another particular embodiment, the non-diabetic female mammal is selected from the group consisting of female mammals having insulin resistance (also known as resistance to insulin or insulinic resistance); when insulin resistance occurs together with hyperglycemia, it can lead to the development of diabetes, nevertheless insulin resistance alone does not lead to a diabetic condition. The female mammals having insulin resistance are preferably selected from the group consisting of female mammals having one or more of the following conditions: obesity or overweight, metabolic syndrome, prediabetes, polycystic ovarian syndrome, hypertension, heart disease, hyperlipidemias or dyslipidemia, hyperthyroidism, hyperparathyroidism, hyperleptinemia or leptin resistance, sedentary life style, eating disorders, obstructive sleep apnea syndrome, fetal malnutrition, Prader-Willi syndrome, Rabson-Mendenhall syndrome, fatty liver, leprechaunism, pathologies associated with excessive glucocorticoid secretion (e.g., acromegaly), insulin resistance caused by pharmacological treatments (e.g., glucocorticoids, thiazide diuretics, beta-blockers), stress or early menarche [Egas Béjar, Daniela et. al Insulinorresistencia/Insulin resistance. Medicina (Guayaquil); 10(2):159-166, April 2005; Graves, Thomas K. WHY ISN'T THIS INSULIN WORKING? Western Veterinary Conference 2013 (SA113); Ximena Gaete V. Adelanto de la pubertad en Chile y el mundo. Rev Chil Pediatr 77 (5); 456-465, 2006; Leszek Szablewski Glucose Homeostasis and Insulin Resistance (elSBN: 978-1-60805-) Bentham e-books]. Many of these indications have been described to be unrelated to infertility, including prediabetes [Acta Diab. Latina 4, 507, 1967].
In the compositions of the invention, the salt or tungsten (VI) salts or a solvate thereof are present at a concentration of at least 100 mg/kg. According to particular embodiments, the salt or tungsten (VI) salts are comprised in the composition at concentrations of at least 150 mg/kg, at least 200 mg/kg, at least 250 mg/kg, at least 300 mg/kg, at least 350 mg/kg, at least 400 mg/kg, at least 450 mg/kg, at least 500 mg/kg, at least 550 mg/kg, at least 600 mg/kg, at least 650 mg/kg, at least 700 mg/kg, at least 750 mg/kg, at least 800 mg/kg, at least 850 mg/kg, at least 900 mg/kg or at least 850 mg/kg.
According to another particular embodiment, the total concentration of tungsten (VI) salts is equal to or less than 1000 mg/kg.
According to another particular embodiment, the food composition will be suitable for the administration of tungsten salts in a daily dose between 0.001 mg per kg of body weight of the female mammal (hereinafter, mg/kg/day) and the maximum tolerated dose for the corresponding female mammal species.
According to a more particular embodiment, the maximum daily dose will be 1000 mg/kg/day; according to additional particular embodiments, the administration would be carried out in doses of at least 0.001 mg/kg/day, at least 0.01 mg/kg/day, at least 0.1 mg/kg/day, at least 0.5 mg/kg/day, at least 1 mg/kg/day, at least 10 mg/kg/day, at least 25 mg/kg/day, at least 50 mg/kg/day, at least 100 mg/kg/day, at least 200 mg/kg/day, at least 300 mg/kg/day, at least 400 mg/kg/day, at least 500 mg/kg/day, at least 600 mg/kg/day, at least 700 mg/kg/day, at least 800 mg/kg/day or at least 900 mg/kg/day.
A third aspect of the invention relates to the use of a tungsten (VI) salt or a solvate thereof, as defined above, for the preparation of a medicinal product for the treatment of infertility in a non-diabetic female mammal or for favoring fertility in a non-diabetic female mammal.
A fourth aspect of the invention relates to a method for the treatment of infertility or for favoring normal reproduction and fertility in a non-diabetic female mammal, which comprises administering a therapeutically effective amount of a tungsten (VI) salt or a solvate thereof, as defined above.
All the definitions and preferred meanings provided above in relation to the first aspect of the invention are applicable to the other aspects of the invention. Therefore, for example, the tungsten (VI) salt will comprise a tungsten (VI) anion and a dietetically or pharmaceutically acceptable cation, which will preferably be an alkaline or alkaline earth cation, even more preferably a sodium, potassium, magnesium and calcium and zinc cation. Particularly, the salt will be tungsten (VI) sodium salt. The tungsten (VI) anion is once again selected from WO4 2−, HWO4 −, WO2O7 2− and HW2O7 − ions, preferably WO4 2−, and in the case of being presented in the form of a solvate, the solvate will preferably be a hydrate, more specifically a dihydrate. The rest of the particular embodiments provided above for the first aspect also relate to other aspects.
A series of non-limiting, illustrative examples of the present invention are included below.
EXAMPLES Example 1. Description of the Animal Model (IRS2−/− Female Mice)
The mouse model used for determining the activity of tungsten (VI) salts for favoring normal reproduction and fertility is an Irs2 gene knock-out mouse, IRS2−/−[Burks et. al., “IRS-2 pathways integrate female reproduction and energy homeostasis”, Nature, 2000, vol. 407, pp. 377-382]. Irs2 gene deletion translates into a clear sexual dimorphism in relation to fertility and carbohydrate metabolism.
The male mice of this model have insulin resistance and severe hyperglycemia that started at an early age. In contrast, the female mice remain relatively euglycemic at an early age and develop slight insulin resistance which remains until a later age (4-5 months). IRS2−/− female mice at an early age, about 10 weeks old, show a low follicular development and persistent anovulation, accompanied by the absence of estrous cycle in most mice. The pregnancy rate in IRS2−/− female mice is 9% compared to the rate of 100% in IRSwt (IRS-2−/− wild type) female mice. Given that female mice at these ages remain euglycemic and that they only develop slight insulin resistance, the profound impairment in fertility is not a direct result of anomalies in glucose metabolism.
The IRS2−/− female mice used are between 6 and 8 weeks of age. The publication by Burks et al, “IRS-2 pathways integrate female reproduction and energy homeostasis”, Nature, 2000, vol. 407, pp. 377-382, describes that, while IRS2−/− male mice were already highly glucose intolerant at 6 weeks of age, IRS2−/− female mice maintained baseline glucose levels in the range of 120-160 mg/dl up to 4-5 months of age (page 378, column 1, end of the second paragraph). Additionally, the same publication describes that female mice of less than 10 weeks of age are relatively euglycemic and slightly insulin resistant. Therefore, the profound impairment in fertility in this animal model is not a direct result of an abnormal glucose metabolism in IRS-2−/− female mice. Baseline blood glucose levels of 120-160 mg/dl are considered normal levels [“Ciencia y Tecnologia en protección y experimentación animal”, Ed McGraw-Hill/interamericana de España (2001). ISBN:84-486-0310-9 (page 27): the normal levels in mice are indicated between 63 and 176 mg/dl].
Other more recent studies performed with IRS2−/− mice have studied the mentioned differences existing between male and female mice; for example, Biochemical Pharmacology 2011, 81, 279-288, describes that the circulating insulin levels were not significantly different between wild type mice and IRS2−/− female mice and in response to several glucose concentrations, the response of IRS2−/− female mice in terms of insulin secretion was identical to that of control animals, wild type mice (page 281, column 2, paragraph 1; and page 284, column 2, paragraph 1 of the section entitled “Discussion”), whereas the insulin secretion in IRS2−/− male mice increased in comparison with the wild type controls.
Other studies conducted with this animal model have shown that IRS2 has critical and direct functions on the ovary, particularly in follicular development and ovulation, by means of regulating key components of the cell cycle mechanism that are involved in cell proliferation and differentiation coordination, clearly and directly linking the absence of IRS2 expression with infertility [Biology of Reproduction 2007, 76, 1045-1053].
The IRS2−/− animal model is primarily a beta-cell failure model [Am J Physiol Endocrinol Metab 2014, 306, E36-E47)]. It describes that the progressive loss of beta cells due to the increased number of apoptotic beta cells determine the progression to diabetes in this animal model (see page E36, column 2, paragraph 2), only at advanced ages. The gradual reduction of beta cells is initially compensated for by a higher activity of persisting cells, and only in advanced ages, the decrease in the number of cells cannot be compensated for by the persisting cells, giving rise to the onset of hyperglycemia and the subsequent development of diabetes
Fertility is a complex mechanism involving various factors. There is no “ideal” animal model, but rather many animal models, for example, those marketed by Jackson Laboratories (http://jaxmice.jax.org/list/ra861.html).
An important factor influencing fertility is the leptin hormone which is necessary both for fertility in males and females. The ovulation cycles in females are effected by leptin, and leptin levels out of the ideal range can have a negative effect on ovum quality. The IRS2−/− mice have high circulating leptin levels, which is probably another factor influencing fertility.
Therefore, this animal model covers a series of important infertility-related factors and is a suitable model for studying the efficacy of the compounds on infertility in female mammals.
Example 2. Ovulation, Implantation and Pregnancy Study
A. Animals
Ten IRS2−/− female mice of ages comprised between 6 and 8 weeks. Six “wild-type” (IRS2wt) male mice of ages comprised between 6 and 8 weeks. The female and male mice were housed separately in normal conditions, i.e., a 12 h light/darkness cycle and controlled temperature and humidity. The animals were fed at will (also referred to as ad libitum) with a standard feed diet.
B. Method
Pre-Treatment Phase
After an acclimatization period, the IRS2−/− female mice were housed in groups of 4-6 mice/cage. Tungstate salt-free drinking water was administered to the animals during the pre-treatment phase (2 weeks).
Treatment Phase
Sodium tungstate was administered in the drinking water (ad libitum) by means of a solution of 2 mg/ml of sodium tungstate dihydrate (marketed by Carlo Erba) in distilled water after the pre-treatment phase (day 0 of treatment) and up to 4 weeks before sacrificing the animals. The daily dose of sodium tungstate ingested by the mice was about 180 mg/kg of body weight.
Cross-Breeding
After the first three weeks of treatment, the IRS2−/− female mice were housed in cages in pairs together with a IRS2wt male mouse continuously.
The mice were observed daily to look for signs of pregnancy or birth.
After 4 weeks, the male mice were exchanged between the cages and they were kept therein for another 4 weeks.
The administration of tungstate was maintained for 8 weeks in which male and female mice were housed together. After these 8 weeks, treatment was withdrawn and the male and female mice were housed together for 4 additional weeks.
Sacrifice
After this period, the female mice were sacrificed and biopsy was carried out to look for indications of pregnancy.
C. Results
Results of the Ovulation Study
During the pre-treatment period and during the first 3 weeks of treatment, vaginal smears were performed in 6 randomly chosen female mice on days −8; −5; −2; −1; 7; 8; 14; 15 and 22, to determine the phase of the estrous cycle they were in.
Between 1 and 2 ml of saline solution was introduced into the vagina of the mice with a Pasteur pipette. Vaginal exudate was collected with the same pipette and spread on a slide. Once air-dried, it was fixed and stained with the Papanicolau technique.
The Papanicolau technique comprises staining the vaginal smears fixed on the slide in the following manner:
    • 10 immersions in 50% v/v alcohol;
    • Immersing in Harris hematoxylin solution for 3 minutes;
    • Rinsing with running water;
    • 10 immersions in acid alcohol (1% hydrochloric acid);
    • Rinsing with running water;
    • 10 immersions in 95% v/v alcohol;
    • Immersing in OG-6 solution for 30 seconds;
    • 10 immersions in 96% v/v alcohol;
    • Immersing in eosin solution for 1 minute;
    • 10 immersions in 96% v/v alcohol;
    • 10 immersions in 86% v/v alcohol; and
    • 10 immersions in xylol
The preparations were analyzed by trained staff using a coding in a single-blind manner for eliminating observer bias.
The samples were identified in the following phases: diestrus, proestrus, estrus, metestrus, anestrus or non-evaluable. The cyclical nature of the four phases in periods of 4 to 6 days are indicative of a normal estrous cycle, whereas the absence of this cyclical nature and the persistence in anestrus, diestrus or proestrus phases are indicative of the absence of estrous cycle.
Of the 10 female mice subjected to study, Table 1 summarizes the phases of the estrous cycle in the vaginal smears performed in 6 of these IRS2−/− female mice.
TABLE 1
Mouse Time (days)
No. −8 −5 −2 −1 7 8 14 15 22
72 A A P D E E-M E E A
898 D D P P E E E-M M M
926 D D P P E-M E-M D E P
928 D-P D P P E E E-M M A
942 A D P P E E-M E-M A D
972 D D — P M M — D D
The phases of the estrous cycle are the following: A: Anestrus; D: Diestrus; P: Proestrus; E: Estrus; and M: Metestrus.
The phases of the estrous cycle found in the vaginal smears of the IRS2−/− female mice of Table 1 show that during the pre-treatment period all the mice were in the proestrus (P) or diestrus (D) phase, i.e., with the absence of estrous cycle.
However, after starting the administration of tungstate, it is observed that the IRS2−/− female mice are in the late phases of estrous cycle, i.e., estrus (E) and metestrus (M) phases, which is indicative of the recovery of a normal estrous cycle.
These results indicate that the administration of a tungsten (VI) salt allows quick recovery (on the seventh day of treatment) of the estrous cycle in infertile, non-diabetic IRS2−/− female mice in 100% of analyzed mice.
Results of the Implantation and Pregnancy Study
After the cross-breeding period of the method of section B, the female mice were sacrificed and biopsies were carried out to look for indications of pregnancy.
Table 2 summarizes the age at the time of treatment, whether or not there was pregnancy and the number of embryos per female mouse.
TABLE 2
Age (months) Number
at the start of of embryos
Mouse cross- implanted or
No. treatment breeding Pregnancy young born
72 10 12 YES 1 young
942 10 12 YES 8 young
928 10 12 YES 7 embryos
931 10 12 YES 3 young
898 10 12 YES 7 embryos
900 10 12 NO —
921 10 12 YES 6 embryos
926 10 12 YES 8 young
972 8 10 NO —
973 8 10 YES 7 embryos
The results of Table 2 show that while the pregnancy rate in untreated IRS2−/− female mice is 9%, the pregnancy rate in IRS2−/− female mice treated with tungstate increases to 80%.
Furthermore, these results also show that the mean of young/implanted embryos per pregnant female mouse is about 5, a number which can be considered comparable to the number of young of a female mouse.
Therefore, the results of Tables 1 and 2 demonstrate that tungsten (VI) salt is an effective treatment for recovering ovulation and/or increasing oocyte implantation. Therefore, the administration of a tungsten (VI) salt as defined in the present invention is effective for the treatment of infertility in non-diabetic female mammals.
Example 3. Glycemia and Body Weight Study
A. Animals
Six IRS2−/− female mice of ages comprised between 6 and 8 weeks.
The female mice were housed in normal conditions, i.e., a 12 h light/darkness cycle and controlled temperature and humidity. The animals were fed at will (also referred to as ad libitum) with a standard feed diet.
B. Method
Treatment Phase
After an acclimatization period, sodium tungstate was administered in the drinking water (ad libitum) by means of a solution of 2 mg/ml of sodium tungstate dihydrate (marketed by Carlo Erba) in distilled water after the pre-treatment phase (day 0 of treatment) and for 12 days.
C. Results
The body weight was monitored on days 0, 2, 5, 7, 9 and 12 of the treatment period, and the blood glucose was determined after 6 hours of fasting on each of the aforementioned days by means of drawing blood from the tail vein and with a glucose sensor (AccuTrend glucose sensor, Roche, Mannheim, Germany).
Table 3 summarizes the glycemic levels expressed in mg/dl, and Table 4 summarizes the body weight of the mice under study expressed in grams.
TABLE 3
Glycemia (mg/dl)
Aver-
R1327 R1345 R1347 R1354 R1376 R1381 age
Day 0 146 129 115 126 141 112 128,17
Day 2 136 128 118 110 105 107 117,33
Day 5 125 142 114 111 137 105 122,33
Day 7 140 110 106 89 133 135 118,83
Day 9 125 153 109 108 131 125 125,17
Day 12 136 116 111 86 123 141 118,83
TABLE 4
Body weight (g)
Aver-
1327 1345 1347 1354 1376 1381 age
Day 0 22.7 15.33 18.21 16.5 13.99 15.45 17.03
Day 2 22.9 14.84 18.98 17.01 14.18 16.04 17.33
Day 5 22.61 14.89 18.2 16.61 13.79 15.72 16.97
Day 7 22.42 15.07 17.81 16.35 13.74 15.66 16.84
Day 9 22.85 15.56 17.9 16.89 14.5 16.39 17.35
Day 12 23.15 15.91 18.24 17.19 14.92 16.89 17.72
The results of Tables 3 and 4 show that during the administration of sodium tungstate no variations were observed in the body weight or in the glycemia in the first 12 days of treatment, the same period in which ovulation is successfully re-established in the tested female mice from day 7 of treatment (cf. Table 1).
Therefore, the results of Tables 1 to 4 demonstrate that a tungsten (VI) salt is a treatment effective for recovering ovulation and/or increasing oocyte implantation, regardless of the changes in body weight and in carbohydrate metabolism. It is therefore demonstrated that the administration of a tungsten (VI) salt as defined in the present invention or a composition containing such tungsten (VI) salt has a direct effect on the female reproductive system and is therefore effective for favoring normal reproduction and fertility in non-diabetic female mammals.
Example 4. Endometrial Embryonic Adhesion Study
A. Model
An “in vitro” human-human embryonic adhesion model made up the HEC1-A endometrial cell line and the JEG-3 trophectoderm cell line was used to determine the effect of sodium tungstate on endometrial receptivity.
The use of in vitro models, and specifically the model based on the mentioned cell lines (HEC-1A and JEG-3), is considered a standard model for studying endometrial receptivity and particularly the adhesion the trophoblast to the endometrium (Fertility and Sterility 2011; 96, 522-529; Methods in Enzymology 2006; 420:3-18 or FASEB J. 201; 26:3715-3727).
The JEG-3 cell line which simulates the trophectoderm cells of a human embryo are cells that grow in monolayers in laboratory using low adherence plates and are capable of forming spheroids simulating the human embryo; this is one of the most widely used cell lines for conducting in vitro embryonic adhesion assay.
B. Method
The cell lines were commercially purchased (American Type Culture Collection (ATCC); Rockville, Md., USA) for conducting the endometrial embryonic adhesion experiments. They were thawed and expanded in 4 passes for obtaining sufficient cells to perform all the assays.
The HEC1-A cells were plated in 24-well plates and cultured with McCoy 5A culture medium supplemented with 10% fetal bovine serum and 0.1% antibiotics (fungizone and penicillin), until reaching 90% confluence. After reaching the confluence, there was added to the culture medium sodium tungstate at a final concentration of 10 μM, as well as Withaferin A (as a control, a compound that prevents embryonic adhesion) or culture medium (baseline adhesion data), without any additional component, for 24 hours.
The JEG-3 cells were plated in low adherent plates with Eagle's minimal essential medium (EMEM) culture medium supplemented with 10% fetal bovine serum and 0.1% antibiotics (fungizone and penicillin). Twenty-four hours before the adhesion assay, the JEG-3 trophoblast spheroids were formed from this culture. To that end, JEG-3 cells in the medium described above were suspended in an Erlenmeyer flask under stirring at a concentration of 6×105 cells/6 ml. The resulting spheroids were collected for the adhesion assay.
For the adhesion assay, 24 hours after culturing the HEC-1A cells with culture medium adding sodium tungstate, Withaferin A or without adding any treatment, the culture medium was changed with fresh culture medium without treatments under study. The trophectoderm spheroids were added onto the monolayer of HEC-1A cells, placing 6 to 10 spheroids per well. The adhesion of the spheroids was measured after 60 minutes, counting spheroid that was floating in the culture medium as non-adhered spheroid and spheroid that was not floating as adhered spheroid. The examination was conducted with an inverted microscope (Nikon Diaphot 300; Nikon Corp., Tokyo, Japan). The assay was conducted in triplicate.
C. Results
The results obtained are listed in Table 5. A higher percentage of embryonic adhesion was observed in the conditions in which the HEC-1A lines were treated with sodium tungstate with respect to those in which they were not treated. No adhesion whatsoever is observed in cells treated with the negative control (C−), Withaferin A.
TABLE 5
Absolute adhesion rates
Exp 1 Exp 2 Exp 3 Mean
Baseline adhesion 12% 48% 31% 30%
10 μM sodium tungstate 31% 65% 35% 44%
Withaferin A (C—)  0%  0%  0%  0%
Particular Compositions of the Invention
Food compositions according to the invention are prepared below in an illustrative manner. They must in no way be interpreted as limiting the scope of the invention.
Example 5
A tungsten salt-enriched salad dressing is prepared. An amount of 25 mg of Na2WO4 (100 mg/kg) is added to 250 grams of a commercially available dressing and it is mechanically stirred for 30 minutes.
Example 6
A tungsten salt-enriched ketchup-type salsa is prepared. To that end, 170 mg of CaWO4 are added to 200 grams of commercially available ketchup and it is mechanically stirred for 1 hour.
Example 7
A tungsten salt-enriched milk is prepared. To that end, 1 kg of whole cow's milk is provided, 150 mg of ZnWO4 are added and it is mechanically stirred for 20 minutes. It is recommended to shake the packaging immediately before consumption.
Example 8
A tungsten salt-enriched fruit juice is prepared. Five-hundred mg of MgWO4 are added to 1 kg of commercial juice and it is mechanically stirred for 10 minutes. It is recommended to shake the packaging immediately before consumption.
Example 9
Coated tablets with the following composition are prepared:
PH200 Microcrystalline cellulose (diluent/gliding agent) 250.00 mg
Colloidal anhydrous silica (gliding agent/adsorbent) 3.00 mg
Magnesium stearate (lubricant) 5.00 mg
Talc (lubricant) 7.00 mg
Opadry® white (Opadry® and-1-7000 White)(*) (coating film) 8.00 mg
Sodium tungstate dihydrate 200.00 mg
(*) mixture of hydroxypropylmethylcellulose, polyethylene glycol 6000 and titanium dioxide (E-171)
Example 10
Effervescent tablets with the following composition are prepared:
Sorbitol, aspartame, sucralose and xylitol (sweeteners) 0.025 mg per 10 mg
Calcium carbonate 0.350 mg per 10 mg
Citric acid (acidulant) 0.650 mg per 10 mg
Sodium acid carbonate (acidity regulator) 0.350 mg per 10 mg
Orange flavoring 0.25 mg per 10 mg
Tungsten salt
Example 11
Gelatin capsules with the following composition are prepared:
Nifedipine 6 mg
Xanthan gum 5 mg
Orange flavoring 0.3 mg
Citric acid 0.4 mg
Gelucire 44/14 90 mg
PH10 microcrystalline cellulose (diluent) 92.00 mg/capsule
Sodium tungstate dihydrate 100.00 mg/capsule

Claims (18)

The invention claimed is:
1. A method for favoring normal reproduction and fertility or for increasing efficacy of an assisted reproductive technique in a non-diabetic female mammal, said method comprising administering to said mammal tungsten (VI) salt, or a solvate thereof;
wherein said salt is administered at a daily dose of between 0.001 mg and 1000 mg of the tungsten (VI) salt per kg of body weight of the mammal;
wherein said mammal is not infertile,
wherein the normal reproduction and fertility is a state of fertility in which pregnancy is achieved in a period of 12 months of regular, unprotected sexual intercourse; and
wherein the assisted reproductive technique is selected from a technique comprising induction of ovulation, artificial insemination or in vitro fertilization;
such that the normal reproduction and fertility in said mammal is favored or the efficacy of said assisted reproductive technique in said mammal is increased.
2. The method according to claim 1, wherein the mammal is a human.
3. The method according to claim 1, wherein said salt comprises a tungsten (VI) anion and a pharmaceutically, veterinary or dietetically acceptable cation.
4. The method according to claim 1, wherein the cation is an alkaline or alkaline earth cation.
5. The method according to claim 4, wherein the cation is selected from the group consisting of sodium, potassium, magnesium, calcium and zinc.
6. The method according to claim 5, wherein the cation is sodium.
7. The method according to claim 5, wherein the cation is zinc.
8. The method according to claim 3, wherein the tungsten (VI) anion is selected from the group consisting of WO4 2−, HWO4 −, W2O7 2− and HW2O7 − ions.
9. The method according to claim 8, wherein the anion is WO4 2−.
10. The method according to claim 1, wherein the solvate is dihydrate.
11. A method for favoring normal reproduction and fertility or for increasing efficacy of an assisted reproductive technique in a non-diabetic female mammal, said method comprising administering to said mammal a composition comprising a tungsten (VI) salt or a solvate thereof and at least one pharmaceutically, veterinary or dietetically acceptable excipient or vehicle, wherein said mammal is not infertile, such that the normal reproduction and fertility in said mammal is favored or the efficacy of said assisted reproductive technique in said mammal is increased, wherein the tungsten (VI) salt or a solvate thereof is present in said composition at a concentration equal to or greater than 100 mg of the tungsten (VI) salt or a solvate thereof per kg of the composition;
wherein the normal reproduction and fertility is a state of fertility in which pregnancy is achieved in a period of 12 months of regular, unprotected sexual intercourse; and
wherein the assisted reproductive technique is selected from a technique comprising induction of ovulation, artificial insemination or in vitro fertilization.
12. The method according to claim 11, wherein the method is for increasing efficacy of an assisted reproductive technique in a mammal, and wherein the excipient or vehicle is pharmaceutically or veterinary acceptable.
13. The method according to claim 11, wherein the composition is in the form of a pill, a tablet, a pastille, a capsule, a powder, a wafer, an effervescent powder or a tablet, a solution, a suspension, a syrup or a granule.
14. The method according to claim 11, wherein the method is for favoring normal reproduction and fertility in a non-diabetic female mammal, wherein said composition is a food composition.
15. The method according to claim 14, wherein said composition is a liquid composition or a beverage.
16. The method according to claim 14, wherein said composition is a solid composition.
17. The method according to claim 14, wherein said food composition is a nutritional supplement or complement.
18. The method according to claim 11, wherein said composition comprises sucrose.
US15/327,292 2014-07-21 2014-07-21 Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques Active US10376540B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2014/070586 WO2016012632A1 (en) 2014-07-21 2014-07-21 Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques

Publications (2)

Publication Number Publication Date
US20170173074A1 US20170173074A1 (en) 2017-06-22
US10376540B2 true US10376540B2 (en) 2019-08-13

Family

ID=55162540

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/327,292 Active US10376540B2 (en) 2014-07-21 2014-07-21 Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques

Country Status (27)

Country Link
US (1) US10376540B2 (en)
EP (1) EP3173382B1 (en)
JP (1) JP6534439B2 (en)
KR (1) KR102282865B1 (en)
CN (1) CN106715332B (en)
AR (1) AR101252A1 (en)
AU (1) AU2014401750B2 (en)
BR (1) BR112017001287A2 (en)
CA (1) CA2955914C (en)
DK (1) DK3173382T3 (en)
ES (1) ES2940465T3 (en)
FI (1) FI3173382T3 (en)
HR (1) HRP20230223T1 (en)
HU (1) HUE061726T2 (en)
IL (1) IL250212B (en)
LT (1) LT3173382T (en)
MX (1) MX2017000927A (en)
PL (1) PL3173382T3 (en)
PT (1) PT3173382T (en)
RS (1) RS64025B1 (en)
RU (1) RU2679623C2 (en)
SG (1) SG11201700485VA (en)
SI (1) SI3173382T1 (en)
TW (1) TWI709407B (en)
UY (1) UY36222A (en)
WO (1) WO2016012632A1 (en)
ZA (1) ZA201701241B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368577A1 (en) 2022-11-08 2024-05-15 Oxolife, S.L. Process for the preparation of tungsten (vi) salt hydrates

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642A1 (en) 1995-07-26 1997-12-16 Quimica Farm Bayer Sa Tungsten (vi) composition for peroral treatment of diabetes mellitus
US20040131697A1 (en) 2001-05-16 2004-07-08 Ramon Gomis De Barbara Oral compositions for the treatment of obese non-diabetic mammals, including humans
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
US20080206356A1 (en) 2005-07-29 2008-08-28 Universidad De Barcelona Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders
US9675638B2 (en) 2013-01-22 2017-06-13 Oxolife, S.L. Use of tungsten (VI) salts for the treatment of female infertility in non-diabetic mammals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2245374B1 (en) * 1973-07-27 1977-02-25 Anvar
RU2202314C2 (en) * 2001-04-11 2003-04-20 Алексей Иванович Ступко Method for preparing female patients to artificial insemination
WO2004030687A1 (en) * 2002-10-02 2004-04-15 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
EP1523985B1 (en) * 2003-10-17 2010-03-10 Oy Neurofood Ab Non-radioactive strontium agent for treating cancer
US7700280B2 (en) * 2003-12-31 2010-04-20 The Penn State Research Foundation Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
WO2007003007A1 (en) * 2005-07-05 2007-01-11 Adelaide Fertility Centre Pty Ltd Methods and compositions for improving pregnancy outcome
EP2086642B1 (en) * 2006-10-18 2014-06-25 Periness Ltd. Dnase for the treatment of male sub-fertility
ES2551828B1 (en) * 2014-05-21 2016-09-12 Oxolife S.L. Food compositions comprising tungsten salts (VI)

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642A1 (en) 1995-07-26 1997-12-16 Quimica Farm Bayer Sa Tungsten (vi) composition for peroral treatment of diabetes mellitus
US20040131697A1 (en) 2001-05-16 2004-07-08 Ramon Gomis De Barbara Oral compositions for the treatment of obese non-diabetic mammals, including humans
US7122209B2 (en) * 2001-05-16 2006-10-17 Quimica Farmaceutica Bayer S.A. Oral compositions for the treatment of non-diabetic obese mammals, including humans
US20080206356A1 (en) 2005-07-29 2008-08-28 Universidad De Barcelona Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
US9675638B2 (en) 2013-01-22 2017-06-13 Oxolife, S.L. Use of tungsten (VI) salts for the treatment of female infertility in non-diabetic mammals

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Agarwal et al. Oxidative stress and its implications in female infertility-a clinician's perspective. Reprod. BioMed. Online. Nov. 2005;11(5):641-50.
Agarwal et al. Oxidative stress and its implications in female infertility—a clinician's perspective. Reprod. BioMed. Online. Nov. 2005;11(5):641-50.
Ballester et al., Tungstate administration improves the sexual and reproductive function in female rats with streptozotocin-induced diabetes. Hum. Reprod. Aug. 2007;22(8):2128-35.
Burks et al., IRS-2 pathways integrate female reproduction and energy homeostasis. Nature. Sep. 21, 2000;407 (6802):377-82.
González et al., Genetic manipulation of IRS proteins: animal models for understanding the molecular basis of diabetes. Avences en Diabetologia. 2009;25(1):21-26.
International Search Report for Application No. PCT/EP2014/051141, dated May 5, 2014.
International Search Report for Application No. PCT/ES2014/070586, dated Mar. 27, 2015.
Jin, Effect of obesity on reproductive function and improvement of weight loss on reproductive function of woman with obesity but no ovulation. Medicine Health Sciences of Chinese Master's Theses, Full-text Database, E065-103. 11 pages.
Kubota et al., Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes. Nov. 2000;49(11):1880-9.
Sharma et al., Female Infertility: An Overview. IJPSR. 2011;2(1):1-12.
U.S. Appl. No. 14/762,603, filed Jul. 22, 2015, now U.S. Pat. No. 9,675,638, Issued.
Vause et al., Ovulation induction in polycystic ovary syndrome: JOGC. No. 242, May 2010. pp. 495-502.
Withers et al., Disruption of IRS-2 causes type 2 diabetes in mice. Nature. Feb. 26, 1998;391(6670):900-4.

Also Published As

Publication number Publication date
WO2016012632A1 (en) 2016-01-28
EP3173382A4 (en) 2018-03-21
UY36222A (en) 2016-01-29
JP6534439B2 (en) 2019-06-26
HUE061726T2 (en) 2023-08-28
TW201618796A (en) 2016-06-01
CA2955914C (en) 2022-09-06
WO2016012632A9 (en) 2017-05-18
HRP20230223T1 (en) 2023-04-14
MX2017000927A (en) 2017-05-01
PT3173382T (en) 2023-03-10
JP2017523170A (en) 2017-08-17
AU2014401750A1 (en) 2017-02-09
BR112017001287A2 (en) 2018-01-30
US20170173074A1 (en) 2017-06-22
DK3173382T3 (en) 2023-03-13
PL3173382T3 (en) 2023-05-08
IL250212B (en) 2020-06-30
NZ728467A (en) 2021-04-30
KR102282865B1 (en) 2021-07-28
SI3173382T1 (en) 2023-04-28
RU2017105257A (en) 2018-08-21
CN106715332B (en) 2019-01-29
TWI709407B (en) 2020-11-11
ZA201701241B (en) 2022-05-25
FI3173382T3 (en) 2023-03-25
RU2679623C2 (en) 2019-02-12
AR101252A1 (en) 2016-12-07
IL250212A0 (en) 2017-03-30
CA2955914A1 (en) 2016-01-28
EP3173382A1 (en) 2017-05-31
CN106715332A (en) 2017-05-24
KR20170029627A (en) 2017-03-15
AU2014401750B2 (en) 2019-10-24
RS64025B1 (en) 2023-03-31
EP3173382B1 (en) 2023-01-04
RU2017105257A3 (en) 2018-08-21
ES2940465T3 (en) 2023-05-08
LT3173382T (en) 2023-03-27
SG11201700485VA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
Langley-Evans Nutrition: a lifespan approach
CN105792818B (en) For promoting the composition of female fertility
KR101802675B1 (en) A herbal mixtuer extract with improved implantation and use thereof
US10376540B2 (en) Tungsten (VI) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques
AU2015263221B2 (en) Food compositions comprising tungsten (VI) salts
Franko et al. Effects of maternal dietary manipulation during different periods of pregnancy on hepatic glucogenic capacity in fetal and pregnant rats near term
NZ728467B2 (en) Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques
Al-Azawi et al. Alpha Lipoic acid role on pituitary testicular function in mice treated with Nitrofurantoin or Methotrexate
KR102127290B1 (en) Composition comprising fibroblast growth factor 2(FGF2) for improving pregnancy
ES2639588B1 (en) Use of a tungsten salt (VI) to promote fertility and normal reproduction in a non-diabetic female mammal
青木悠介 et al. Effect of Lepidium meyenii on in vitro fertilization via improvement in acrosome reaction and motility of mouse and human sperm
Ali et al. EFFECT OF AQUEOUS AND ALCOHOLIC EXTRACTS OF COTTONSEED ON SOME PARAMETERS OF SPERMS AND REPRODUCTIVE PERFORMANCE OF ALBINO MICE.
Otašević et al. Impact of nutrition on human fertility
JP2019034924A (en) Agent for improving health condition of pregnant mother and fetus
NZ719680B2 (en) Composition useful for promoting female fertility
Ali et al. Teratogenic effects of vitamin A on embryos of pregnant rats
Mayel-Afshar The effects of dietary protein deficiency on dynamic aspects of protein metabolism in pregnant rats

Legal Events

Date Code Title Description
AS Assignment

Owner name: OXOLIFE, S.L., SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CANALS ALMAZAN, IGNACIO;ARBAT BUGIE, AGNES;SIGNING DATES FROM 20170406 TO 20170407;REEL/FRAME:042149/0400

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4